National Institutes of Health
The purpose of this notice of funding opportunity (NOFO) is to support applications to continue the Immune Tolerance Network (ITN). The primary objective of the Network is to develop tolerogenic therapies for immune-mediated disorders. The three main clinical areas of work are: 1) Allergic diseases and asthma; 2) Autoimmune diseases; and 3) Immune-mediated consequences of transplantation. The core functions of the ITN include designing, conducting, and sharing the results of clinical trials and performing integrated mechanistic studies.
Varies, see official page
Total program funding: $21,986,000
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Who can apply: Government & Tribal, Schools & Colleges, Small Businesses, Nonprofits, For-Profit Businesses
Nationwide (USA)
Federal Government
Apply through Grants.gov. Your organization needs active SAM.gov (UEI) and Grants.gov registrations. These can take several weeks, so start early.
Substance Abuse and Mental Health Services Adminis
The purpose of this program is to support organizations in mobilizing and connecting community resources to increase access to long-term recovery support for people with substance use disorders and co-occurring substance use and mental disorders.
Last verified Oct 23, 2026
National Science Foundation (SBIR)
Last verified Oct 23, 2026
U.S. Department of Health and Human Services (SBIR)
The purpose of this topic is to spur the development of novel, rapid diagnostic assays for multi-system autoimmune disease, which represents an unmet healthcare need. Moreover, in its ideal embodiment this diagnostic test might allow typical primary care...
Last verified Oct 23, 2026
National Institutes of Health
The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.
Last verified Oct 23, 2026
